Teva and Celltrion Launch Herzuma (biosimilar- trastuzumab) in the US
Shots:
- Teva and Celltrion report the availability of Herzuma (trastuzumab-pkrb)- a biosimilar referencing Herceptin in the US. The biosimilar is designed to treat the same indications as to reference product relating to breast cancer and gastric cancer
- The drug will be available at WAC of $1-402.50 for a 150mg dosage and $3-927 for a 420mg dosage- representing a 10% discount on the WAC of Herceptin
- Herzuma (trastuzumab-pkrb) is a biosimilar referencing Herceptin- with no differences in safety- purity and potency. In Oct’2016- the companies signed an exclusive partnership to commercialize Herzuma in the US & Canada
Click here to read full press release/ article
Ref: Teva | Image: Celltrion
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com